TET2 and leukemia: Although TET2 mutations are widely prevalent in CMML (~60%), thus far, they have not been shown to independently impact either OS or leukemia-free survival (LFS).7 In a recent study, TET2 mutations were seen in 46% of CMML patients and the absence of TET2 mutations negatively impacted OS.